Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes.

"Declarations Conflict of interestThe author(s) declared no potential conflict of interest with respect to the research, authorship, and/or publication of this article. Ethical approvalAll named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Editorial assistance was provided by CORESEARCH SRL (Maria Chiara Rossi, Giusi Graziano) through a Novo Nordisk S.p.A. unconditional grant. The authors of the publication are fully responsible for the contents and conclusions. Novo Nordisk S.p.A. did not influence and has not been involved in the data interpretation presented in the manuscript. Informed consentAll procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. The study protocol was approved by the ethics committee of the “S. Camillo-Forlanini” Hospital, Rome, Italy (Prot. 840 CE Lazio 1 – June 12th, 2021). Informed consent was obtained from all patients for being included in the study. Conflict of interest The author(s) declared no potential conflict of interest with respect to the research, authorship, and/or publication of this article."

"Funding The author(s) received no financial support for the research, authorship, and/or publication of this article."